CERID-led experimental medicine trial on the use of clofazimine to treat cryptosporidiosis has completed enrollment and entered the data analysis phase.
May 1, 2019
Dr. Javeed Shah and Dr. David Koelle were recently awarded NIH grants.
April 26, 2019
Join us for CERID Seminars -- the 2nd & 4th Fridays of the month
April 4, 2019
The article highlights the development of methionyl tRNA-synthetase inhibitors for the treatment of Cryptosporidiosis.
April 1, 2019
The study found that seeking care from traditional healers was a strong predictor of advanced HIV disease and that although the majority of study participants presented with advanced disease, there were numerous missed opportunities to prevent HIV-associated morbidity and mortality.
March 22, 2019
Lysyl-tRNA synthetase validated as an effective target against malaria and cryptosporidiosis.
February 19, 2019
Dr. Wes Van Voorhis, Director of CERID, recently reflected on some exciting developments within CERID.
January 29, 2019
CERID Researchers published in The Journal of Infectious Diseases: "Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis."
December 18, 2018
Researchers explore the latest advances in Cryptosporidium research at Tufts University.
October 31, 2018
Dr. Wes Van Voorhis is conducting a Phase 2A, clinical trial on the safety, tolerability, pharmacokinetics and efficacy of clofazimine in Cryptosporidiosis.